Publications

Bedini A, Elisi GM, Fanini F, Retini M, Scalvini L, Pasquini S, Contri C, Varani K, Spadoni G, Mor M, Vincenzi F, Rivara S. Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence. J Pineal Res. 2024 Mar;76(2):e12941. doi: 10.1111/jpi.12941.

Fotio Y, Mabou Tagne A, Squire E, Lee HL, Phillips CM, Chang K, Ahmed F, Greenberg AS, Villalta SA, Scarfone VM, Spadoni G, Mor M, Piomelli D. NAAA-regulated lipid signaling in monocytes controls the induction of hyperalgesic priming in mice. Nat Commun. 2024 Feb 24;15(1):1705. doi: 10.1038/s41467-024-46139-5.

Medrano FJ, de la Hoz-Rodríguez S, Martí S, Arafet K, Schirmeister T, Hammerschmidt SJ, Müller C, González-Martínez Á, Santillana E, Ziebuhr J, Romero A, Zimmer C, Weldert A, Zimmermann R, Lodola A, Świderek K, Moliner V, González FV.Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2. Commun Chem. 2024 Jan 18;7(1):15. doi: 10.1038/s42004-024-01104-7

Tognolini M, Lodola A, Giorgio C. Drug discovery: In silico dry data can bypass biological wet data? Br J Pharmacol. 2024 Feb;181(3):340-344. doi: 10.1111/bph.16266.

La Monica S, Vacondio F, Eltayeb K, Lodola A, Volta F, Viglioli M, Ferlenghi F, Galvani F, Galetti M, Bonelli M, Fumarola C, Cavazzoni A, Flammini L, Verzè M, Minari R, Petronini PG, Tiseo M, Mor M, Alfieri R.Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models. Sci Rep. 2024 Mar 18;14(1):6491. doi: 10.1038/s41598-024-57028-8

Eltayeb K, Alfieri R, Fumarola C, Bonelli M, Galetti M, Cavazzoni A, Digiacomo G, Galvani F, Vacondio F, Lodola A, Mor M, Minari R, Tiseo M, La Monica S, Giorgio Petronini P. Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines. Biochem Pharmacol. 2024 Mar 24:116161. doi: 10.1016/j.bcp.2024.116161.

Barbetti M, Mancabelli L, Vacondio F, Longhi G, Ferlenghi F, Viglioli M, Turroni F, Carnevali L, Mor M, Ventura M, Sgoifo A, Rivara S. Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Apr 20;131:110963. doi: 10.1016/j.pnpbp.2024.110963.

Cammarota M, Ferlenghi F, Vacondio F, Vincenzi F, Varani K, Bedini A, Rivara S, Mor M, Boscia F. Combined targeting of fatty acid amide hydrolase and melatonin receptors promotes neuroprotection and stimulates inflammation resolution in rats. Br J Pharmacol. 2023 May;180(10):1316-1338. doi: 10.1111/bph.16014. Epub 2023 Jan 6.

Guidetti L, Zappia A, Scalvini L, Ferrari FR, Giorgio C, Castelli R, Galvani F, Vacondio F, Rivara S, Mor M, Urbinati C, Rusnati M, Tognolini M, Lodola A. Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity. J Chem Inf Model. 2023 Nov 13;63(21):6900-6911. doi: 10.1021/acs.jcim.3c01064. 

Carnevali L, Barbetti M, Fotio Y, Ferlenghi F, Vacondio F, Mor M, Piomelli D, Sgoifo A.  Enhancement of peripheral fatty acyl ethanolamide signaling prevents stress-induced social avoidance and anxiety-like behaviors in male rats. Psychopharmacology (Berl). 2023 Nov 7. doi: 10.1007/s00213-023-06473-w. 

Mancabelli L, Taurino G, Ticinesi A, Ciociola T, Vacondio F, Milani C, Fontana F, Lugli GA, Tarracchini C, Alessandri G, Viappiani A, Bianchi M, Nouvenne A, Chetta AA, Turroni F, Meschi T, Mor M, Bussolati O, Ventura M. Disentangling the interactions between nasopharyngeal and gut microbiome and their involvement in the modulation of COVID-19 infection. Microbiol Spectr. 2023 Sep 20;11(5):e0219423. doi: 10.1128/spectrum.02194-23. 

Mugnaini C, Kostrzewa M, Casini M, Kumar P, Catallo V, Allarà M, Guastaferro L, Brizzi A, Paolino M, Tafi A, Kapatais C, Giorgi G, Vacondio F, Mor M, Corelli F, Ligresti A.Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 Receptor. Molecules 2023 Jun 24;28(13):4958. doi: 10.3390/molecules28134958.

Papa A, Pasquini S, Galvani F, Cammarota M, Contri C, Carullo G, Gemma S, Ramunno A, Lamponi S, Gorelli B, Saponara S, Varani K, Mor M, Campiani G, Boscia F, Vincenzi F, Lodola A, Butini S. Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions. Eur J Med Chem. 2023, 246:114952. doi: 10.1016/j.ejmech.2022.114952.

Galvani F, Pala D, Cuzzolin A, Scalvini L, Lodola A, Mor M, Rizzi A. Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations. J Chem Inf Model. 2023, 63:2842-2856. doi: 10.1021/acs.jcim.3c00042. 

Ferrari FR, Giorgio C, Zappia A, Ballabeni V, Bertoni S, Barocelli E, Scalvini L, Galvani F, Mor M, Lodola A, Tognolini M. Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach. Biochem Pharmacol. 2023, 209:115452. doi: 10.1016/j.bcp.2023.115452. 

Arafet K, Scalvini L, Galvani F, Martí S, Moliner V, Mor M, Lodola A. Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents. J Chem Inf Model. 2023, 63:1301-1312. doi: 10.1021/acs.jcim.2c01586.

Rusnati M, Paiardi G, Tobia C, Urbinati C, Lodola A, D'Ursi P, Corrado M, Castelli R, Wade RC, Tognolini M, Chiodelli P. Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Ther. 2022, 29:908-917. doi: 10.1038/s41417-021-00379-5.

Galvani F, Scalvini L, Rivara S, Lodola A, Mor M. Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency. J Chem Inf Model. 2022, 62, 2771-2787. doi: 10.1021/acs.jcim.2c00140.

Guidetti L, Castelli R, Scalvini L, Ferlenghi F, Corrado M, Giorgio C, Tognolini M, Lodola A. Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. Pharmaceuticals (Basel) 2022, 15, 137. doi: 10.3390/ph15020137.

Elisi GM, Scalvini L, Lodola A, Mor M, Rivara S. Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors. J Chem Inf Model. 2022, 62, 210-222. doi: 10.1021/acs.jcim.1c01183.

Martí S, Arafet K, Lodola A, Mulholland AJ, Świderek K, Moliner V. Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 Mpro Explored by QM/MM Simulations. ACS Catal. 2022 12, 698-708. doi: 10.1021/acscatal.1c04661.

Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S. In silico drug discovery of melatonin receptor ligands with therapeutic potential. Expert Opin Drug Discov. 2022, 17, 343-354. doi: 10.1080/17460441.2022.2043846.

Ferlenghi F, Giorgio C, Incerti M, Guidetti L, Chiodelli P, Rusnati M, Tognolini M, Vacondio F, Mor M, Lodola A. Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. Pharmaceuticals (Basel). 2022 15, 41. doi: 10.3390/ph15010041.

Fotio Y, Jung KM, Palese F, Obenaus A, Tagne AM, Lin L, Rashid TI, Pacheco R, Jullienne A, Ramirez J, Mor M, Spadoni G, Jang C, Hohmann AG, Piomelli D. NAAA-regulated lipid signaling governs the transition from acute to chronic pain. Sci Adv. 2021 Oct 22;7(43):eabi8834. doi: 10.1126/sciadv.abi8834

Ferlenghi F, Scalvini L, Vacondio F, Castelli R, Bozza N, Marseglia G, Rivara S, Lodola A, La Monica S, Minari R, Petronini PG, Alfieri R, Tiseo M, Mor M. A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. Eur J Med Chem. 2021, 225, 113786. doi: 10.1016/j.ejmech.2021.113786.

Sacco A, Federico C, Giacomini A, Caprio C, Maccarinelli F, Todoerti K, Favasuli V, Anastasia A, Motta M, Russo D, Rossi G, Bozza N, Castelli R, Neri A, Ronca R, Cattaneo C, Tucci A, Mor M, Presta M, Roccaro AM. Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. Blood. 2021 May 6;137(18):2495-2508. doi: 10.1182/blood.2020008414.

Diotallevi A, Scalvini L, Buffi G, Pérez-Pertejo Y, De Santi M, Verboni M, Favi G, Magnani M, Lodola A, Lucarini S, Galluzzi L. Phenotype Screening of an Azole-bisindole Chemical Library Identifies URB1483 as a New Antileishmanial Agent Devoid of Toxicity on Human Cells. ACS Omega. 2021, 6, 35699-35710. doi: 10.1021/acsomega.1c05611.

Chan HTH, Moesser MA, Walters RK, Malla TR, Twidale RM, John T, Deeks HM, Johnston-Wood T, Mikhailov V, Sessions RB, Dawson W, Salah E, Lukacik P, Strain-Damerell C, Owen CD, Nakajima T, Świderek K, Lodola A, Moliner V, Glowacki DR, Spencer J, Walsh MA, Schofield CJ, Genovese L, Shoemark DK, Mulholland AJ, Duarte F, Morris GM. Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding. Chem Sci. 2021, 12, 13686-13703. doi: 10.1039/d1sc03628a.

Ferlenghi F, Mari M, Gobbi G, Elisi GM, Mor M, Rivara S, Vacondio F, Bartolucci S, Bedini A, Fanini F, Spadoni G. N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. ChemMedChem. 2021 Oct 6;16(19):3071-3082. doi: 10.1002/cmdc.202100405.

Ieguchi K, Tomita T, Takao T, Omori T, Mishima T, Shimizu I, Tognolini M, Lodola A, Tsunoda T, Kobayashi S, Wada S, Maru Y. Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions. Int J Mol Sci. 2021;22(5):2480. doi: 10.3390/ijms22052480.

Castelli R, Taranto S, Furiassi L, Bozza N, Marseglia G, Ferlenghi F, Rivara S, Retini M, Bedini A, Spadoni G, Matarazzo S, Ronca R, Presta M, Mor M, Giacomini A. Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. Eur J Med Chem. 2021 Oct 5;221:113529. doi: 10.1016/j.ejmech.2021.113529.

Arafet K, Serrano-Aparicio N, Lodola A, Mulholland AJ, Swiderek K, Moliner V. Mechanism of inhibition of SARS-CoV-2 Mpro byN3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Chem Sci, 2021, 12, 1433–1444. doi: 10.1039/d0sc06195f.

Ghidini A, Scalvini L, Palese F, Lodola A, Mor M, Piomelli D. Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase. J Enzyme Inhib Med Chem. 2021, 36, 1411-1423. doi: 10.1080/14756366.2021.1912.

Giorgio C, Allodi M, Palese S, Grandi A, Tognolini M, Castelli R, Lodola A, Flammini L, Cantoni AM, Barocelli E, Bertoni S. UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling. Pharmaceuticals (Basel). 2021, 14, 502. doi: 10.3390/ph14060502.

Fantoni T, Bernardoni S, Mattellone A, Martelli G, Ferrazzano L, Cantelmi P, Corbisiero D, Tolomelli A, Cabri W, Vacondio F, Ferlenghi F, Mor M, Ricci A. Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend. ChemSusChem. 2021 Jun 21;14(12):2591-2600. doi: 10.1002/cssc.202100623.

Piomelli D, Scalvini L, Fotio Y, Lodola A, Spadoni G, Tarzia G, Mor M. N-acylethanolamine Acid Amidase (NAAA): Structure, Functions and Inhibition. J Med Chem. 2020, doi: 10.1021/acs.jmedchem.0c00191

Ronca R, Ghedini GC, Maccarinelli F, Sacco A, Locatelli SL, Foglio E, Taranto S, Grillo E, Matarazzo S, Castelli R, Paganini G, Desantis V, Cattane N, Cattaneo A, Mor M, Carlo-Stella C, Belotti A, Roccaro A, Presta M, Giacomini A. FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. Cancer Res. 2020, doi: 10.1158/0008-5472.

Lodola A, Callegari D, Scalvini L, Rivara S, Mor M. Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations. Methods Mol Biol. 2020, 2114:307-337. doi: 10.1007/978-1-0716-0282-9_19.

Giorgio C, Zanotti I, Lodola A, Tognolini M. Ephrin or not? Six tough questions on Eph targeting. Expert Opin Ther Targets. 2020 Mar 20. doi: 10.1080/14728222.2020.1745187

Carnevali L, Statello R, Vacondio F, Ferlenghi F, Spadoni G, Rivara S, Mor M, Sgoifo A. Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. Eur Neuropsychopharmacol. 2020 doi: 10.1016/j.euroneuro.2019.12.119. 

Ferlenghi F, Castelli R, Scalvini L, Giorgio C, Corrado M, Tognolini M, Mor M, Lodola A, Vacondio F. Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. J Pharm Biomed Anal. 2020 doi: 10.1016/j.jpba.2019.113067

Castelli R, Scalvini L, Vacondio F, Lodola A, Anselmi M, Vezzosi S, Carmi C, Bassi M, Ferlenghi F, Rivara S, Møller IR, Rand KD, Daglian J, Wei D, Dotsey EY, Ahmed F, Jung KM, Stella N, Singh S, Mor M, Piomelli D. Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. J Med Chem. 2020. doi: 10.1021/acs.jmedchem.9b01679. 

 

Sartini S, Levati E, Maccesi M, Guerra M, Spadoni G, Bach S, Benincasa M, Scocchi M, Ottonello S, Rivara S, Montanini B. New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform. ACS Chem Biol. 2019 Aug 16;14(8):1727-1736. doi: 10.1021/acschembio.9b00178.

Marseglia G, Lodola A, Mor M, Castelli R. Fibroblast growth factor receptor inhibitors: patent review (2015-2019). Expert Opin Ther Pat. 2019 Dec;29(12):965-977. doi: 10.1080/13543776.2019.1688300.

Vozella V, Ahmed F, Choobchian P, Merrill CB, Zibardi C, Tarzia G, Mor M, Duranti A, Tontini A, Rivara S, Piomelli D. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. J Pharm Pharmacol. 2019 Dec;71(12):1762-1773. doi: 10.1111/jphp.13166. 

Rezzola S, Ronca R, Loda A, Nawaz MI, Tobia C, Paganini G, Maccarinelli F, Giacomini A, Semeraro F, Mor M, Presta M. The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. Cancers (Basel). 2019 Sep 4;11(9). pii: E1305. doi: 10.3390/cancers11091305.

Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent with Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. 

Castelli R, Bozza N, Cavazzoni A, Bonelli M, Vacondio F, Ferlenghi F, Callegari D, Silva C, Rivara S, Lodola A, Digiacomo G, Fumarola C, Alfieri R, Petronini PG, Mor M. Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. Eur J Med Chem. 2019 Jan 15;162:507-524. doi: 10.1016/j.ejmech.2018.11.029. 

Grandi A, Zini I, Palese S, Giorgio C, Tognolini M, Marchesani F, Bruno S, Flammini L, Cantoni AM, Castelli R, Lodola A, Fusari A, Barocelli E, Bertoni S. Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD. Front Pharmacol. 2019 Jun 17;10:691. doi: 10.3389/fphar.2019.00691

Callegari D, Ranaghan KE, Woods CJ, Minari R, Tiseo M, Mor M, Mulholland AJ, Lodola A. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib. Chem Sci. 2018 Feb 12;9(10):2740-2749. doi: 10.1039/c7sc04761d

Messore A, Madia VN, Pescatori L, Saccoliti F, Tudino V, De Leo A, Bortolami M, De Vita D, Scipione L, Pepi F, Costi R, Rivara S, Scalvini L, Mor M, Ferrara FF, Pavoni E, Roscilli G, Cassinelli G, Milazzo FM, Battistuzzi G, Di Santo R, Giannini G. Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity. J Med Chem. 2018 Dec 13;61(23):10834-10859. doi: 10.1021/acs.jmedchem.8b01497. 

Elisi GM, Santucci M, D'Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML, Mor M, Costi MP. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers (Basel). 2018 Sep 14;10(9). pii: E329. doi: 10.3390/cancers10090329. 

Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, Delle Monache S, Maturo MG, Sferra R, Chiodelli P, Rusnati M, Cantoni A, Castelli R, Vacondio F, Lodola A, Tognolini M. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget. 2018 May 11;9(36):24347-24363. doi: 10.18632/oncotarget.25272. 

Spadoni G, Bedini A, Furiassi L, Mari M, Mor M, Scalvini L, Lodola A, Ghidini A, Lucini V, Dugnani S, Scaglione F, Piomelli D, Jung KM, Supuran CT, Lucarini L, Durante M, Sgambellone S, Masini E, Rivara S.Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. J Med Chem. 2018 Sep 13;61(17):7902-7916. doi: 10.1021/acs.jmedchem.8b00893. 

Saxena P, Severi L, Santucci M, Taddia L, Ferrari S, Luciani R, Marverti G, Marraccini C, Tondi D, Mor M, Scalvini L, Vitiello S, Losi L, Fonda S, Pacifico S, Guerrini R, D'Arca D, Ponterini G, Costi MP. Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. J Med Chem. 2018 Aug 23;61(16):7374-7380. doi: 10.1021/acs.jmedchem.7b01699. 

Ainsley J, Lodola A, Mulholland AJ, Christov CZ, Karabencheva-Christova TG. Combined Quantum Mechanics and Molecular Mechanics Studies of Enzymatic Reaction Mechanisms. Adv Protein Chem Struct Biol. 2018; 113:1-32. doi: 10.1016/bs.apcsb.2018.07.00

Madia VN, Messore A, Pescatori L, Saccoliti F, Tudino V, De Leo A, Bortolami M, Scipione L, Costi R, Rivara S, Scalvini L, Mor M, Ferrara FF, Pavoni E, Roscilli G, Cassinelli G, Milazzo FM, Battistuzzi G, Di Santo R, Giannini G. Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. J Med Chem. 2018 Aug 9;61(15):6918-6936. doi: 10.1021/acs.jmedchem.8b00908. 

Rivara S, Scalvini L, Lodola A, Mor M, Caignard DH, Delagrange P, Collina S, Lucini V, Scaglione F, Furiassi L, Mari M, Lucarini S, Bedini A, Spadoni G. Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands. J Med Chem. 2018 Apr 26;61(8):3726-3737. doi: 10.1021/acs.jmedchem.8b00359. 

Nawaz IM, Chiodelli P, Rezzola S, Paganini G, Corsini M, Lodola A, Di Ianni A, Mor M, Presta M. N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. Angiogenesis. 2018 Feb;21(1):47-59. doi: 10.1007/s10456-017-9581-6.

Lodola A, Bertolini S, Biagetti M, Capacchi S, Facchinetti F, Gallo PM, Pappani A, Mor M, Pala D, Rivara S, Visentini F, Corsi M, Capelli AM. Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs. J Med Chem. 2017 May 25;60(10):4304-4315. doi: 10.1021/acs.jmedchem.7b00247. 

Callegari D, Lodola A, Pala D, Rivara S, Mor M, Rizzi A, Capelli AM. Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. J Chem Inf Model. 2017 Jan 12. doi: 10.1021/acs.jcim.6b00679. PMID: 28080056

Castellani B, Diamanti E, Pizzirani D, Tardia P, Maccesi M, Realini N, Magotti P, Garau G, Bakkum T, Rivara S, Mor M, Piomelli D. Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). Chem Commun (Camb). 2017 Nov 28;53(95):12814-12817. doi: 10.1039/c7cc07582k 

Gatti G, Lucini V, Dugnani S, Calastretti A, Spadoni G, Bedini A, Rivara S, Mor M, Canti G, Scaglione F, Bevilacqua A. Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. Oncotarget. 2017 Aug 10;8(40):68338-68353. doi: 10.18632/oncotarget.20124. 

Karabencheva-Christova TG, Torras J, Mulholland AJ, Lodola A, Christov CZ. Mechanistic Insights into the Reaction of Chlorination of Tryptophan Catalyzed by Tryptophan 7-Halogenase. Sci Rep. 2017 Dec 12;7(1):17395. doi: 10.1038/s41598-017-17789-x.

Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. J Med Chem. 2017 Jan 26;60(2):787-796. doi: 10.1021/acs.jmedchem.6b01642.

Scalvini L, Vacondio F, Bassi M, Pala D, Lodola A, Rivara S, Jung KM, Piomelli D, Mor M. Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. Sci Rep. 2016 Aug 8;6:31046. doi: 10.1038/srep31046. PMID: 27499063 

Montanari S, Scalvini L, Bartolini M, Belluti F, Gobbi S, Andrisano V, Ligresti A, Di Marzo V, Rivara S, Mor M, Bisi A, Rampa A. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. J Med Chem. 2016 Jul 14;59(13):6387-406. doi: 10.1021/acs.jmedchem.6b00609. PMID: 27309570

Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. PMID: 27257132

Russo S, Callegari D, Incerti M, Pala D, Giorgio C, Brunetti J, Bracci L, Vicini P, Barocelli E, Capoferri L, Rivara S, Tognolini M, Mor M, Lodola A. Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return. Chemistry. 2016 Jun 6;22(24):8048-52. doi: 10.1002/chem.201600993. PMID: 27139720

Castelli R, Giacomini A, Anselmi M, Bozza N, Vacondio F, Rivara S, Matarazzo S, Presta M, Mor M, Ronca R. Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. J Med Chem. 2016 May 26;59(10):4651-63. doi: 10.1021/acs.jmedchem.5b02021. PMID: 27138345

Tarozzi A, Marchetti C, Nicolini B, D'Amico M, Ticchi N, Pruccoli L, Tumiatti V, Simoni E, Lodola A, Mor M, Milelli A, Minarini A. Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. Eur J Med Chem. 2016 Jul 19;117:283-91. doi: 10.1016/j.ejmech.2016.04.002. 

Carnevali L, Rivara S, Nalivaiko E, Thayer JF, Vacondio F, Mor M, Sgoifo A. Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychological-cardiac comorbidity? Neurosci Biobehav Rev. 2016 Apr 27. pii: S0149-7634(16)30031-8. doi: 10.1016/j.neubiorev.2016.04.013.  

Pala D, Rivara S, Mor M, Milazzo FM, Roscilli G, Pavoni E, Giannini G. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology. 2016 Jun;26(6):640-54. doi: 10.1093/glycob/cww003. 

Mugnaini C, Brizzi A, Ligresti A, Allarà M, Lamponi S, Vacondio F, Silva C, Mor M, Di Marzo V, Corelli F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. J Med Chem. 2016 Feb 11;59(3):1052-67. doi: 10.1021/acs.jmedchem.5b01559. 

Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, Mor M, Pala D, Hassan-Mohamed I, Gioiello A, Rusnati M, Lodola A, Tognolini M. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol. 2016 Jan 1;99:18-30. doi: 10.1016/j.bcp.2015.10.006. 

Carnevali L, Vacondio F, Rossi S, Macchi E, Spadoni G, Bedini A, Neumann ID, Rivara S, Mor M, Sgoifo A. Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety. Sci Rep. 2015 Dec 14;5:18218. doi: 10.1038/srep18218. 

Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, Bertoni S, Giorgio C, Hassan-Mohamed I, Zanotti I, Bugatti A, Rusnati M, Festuccia C, Rivara S, Barocelli E, Mor M, Lodola A. Δ⁵-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. Eur J Med Chem. 2015 Aug 29;103:312-324. doi: 10.1016/j.ejmech.2015.08.048 

Spadoni G, Bedini A, Lucarini S, Mari M, Caignard DH, Boutin JA, Delagrange P, Lucini V, Scaglione F, Lodola A, Zanardi F, Pala D, Mor M, Rivara S. Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. J Med Chem. 2015 Sep 24;58(18):7512-25. doi: 10.1021/acs.jmedchem.5b01066. 

Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, Matarazzo S, Rezzola S, Maiolo D, Torrella R, Moroni E, Mazzieri R, Escobar G, Mor M, Colombo G, Presta M. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell. 2015 Aug 10;28(2):225-39. doi: 10.1016/j.ccell.2015.07.002. 

Vacondio F, Bassi M, Silva C, Castelli R, Carmi C, Scalvini L, Lodola A, Vivo V, Flammini L, Barocelli E, Mor M, Rivara S. Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. PLoS One. 2015 Jun 8;10(6):e0128699. doi: 10.1371/journal.pone.0128699. 

Dotsey EY, Jung KM, Basit A, Wei D, Daglian J, Vacondio F, Armirotti A, Mor M, Piomelli D. Peroxide-Dependent MGL Sulfenylation Regulates 2-AG-Mediated Endocannabinoid Signaling in Brain Neurons. Chem Biol. 2015 May 21;22(5):619-28. doi: 10.1016/j.chembiol.2015.04.013. 

Spadoni G, Bedini A, Lucarini S, Mor M, Rivara S. Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1145-56. doi: 10.1517/17425255.2015.1045487. Epub 2015 May 8. PMID: 25956235

Ribeiro A, Pontis S, Mengatto L, Armirotti A, Chiurchiù V, Capurro V, Fiasella A, Nuzzi A, Romeo E, Moreno-Sanz G, Maccarrone M, Reggiani A, Tarzia G, Mor M, Bertozzi F, Bandiera T, Piomelli D. A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem Biol. 2015 Aug 21;10(8):1838-46. doi: 10.1021/acschembio.5b00114. 

Curti C, Sartori A, Battistini L, Brindani N, Rassu G, Pelosi G, Lodola A, Mor M, Casiraghi G, Zanardi F. Pushing the boundaries of vinylogous reactivity: catalytic enantioselective mukaiyama aldol reactions of highly unsaturated 2-silyloxyindoles. Chemistry. 2015 Apr 20;21(17):6433-42. doi: 10.1002/chem.201500083. 

Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E, Costi MP. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.J Med Chem. 2015 Jun 25;58(12):4857-73. doi: 10.1021/jm501615v.

Capoferri L, Lodola A, Rivara S, Mor M. Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide. J Chem Inf Model. 2015 Mar 23;55(3):589-99. doi: 10.1021/ci500720e. Epub 2015 Feb 17. PMID: 25658136

Lodola A, Rivara S, Mor M. Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods. Adv Protein Chem Struct Biol. 2014;96:219-34. doi: 10.1016/bs.apcsb.2014.06.007. Epub 2014 Aug 24. PMID: 25443959

Giedroyć-Piasecka W, Dyguda-Kazimierowicz E, Beker W, Mor M, Lodola A, Sokalski WA. Physical Nature of Fatty Acid Amide Hydrolase Interactions with Its Inhibitors: Testing a Simple Nonempirical Scoring Model. J Phys Chem B. 2014 Dec 10. [Epub ahead of print] PMID: 25420234

Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M, Lodola A. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. J Chem Inf Model. 2014 Oct 27;54(10):2621-6. doi: 10.1021/ci5004619. 

Giannini G, Vesci L, Battistuzzi G, Vignola D, Milazzo FM, Guglielmi MB, Barbarino M, Santaniello M, Fantò N, Mor M, Rivara S, Pala D, Taddei M, Pisano C, Cabri W. ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. J Med Chem. 2014 Oct 23;57(20):8358-77. doi: 10.1021/jm5008209. 

Pala D, Scalvini L, Lodola A, Mor M, Flammini L, Barocelli E, Lucini V, Scaglione F, Bartolucci S, Bedini A, Rivara S, Spadoni G. Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands. Int J Mol Sci. 2014 Sep 12;15(9):16114-33. doi: 10.3390/ijms150916114. 

Berteotti A, Vacondio F, Lodola A, Bassi M, Silva C, Mor M, Cavalli A. Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. ACS Med Chem Lett. 2014 Feb 24;5(5):501-5. doi: 10.1021/ml400489b. eCollection 2014 May 8. 

Fiasella A, Nuzzi A, Summa M, Armirotti A, Tarozzo G, Tarzia G, Mor M, Bertozzi F, Bandiera T, Piomelli D. 3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. ChemMedChem. 2014 Jul;9(7):1602-14. doi: 10.1002/cmdc.201300546. 

Damiano F, Silva C, Gregori A, Vacondio F, Mor M, Menozzi M, Di Giorgio D. Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. Sci Justice. 2014 May;54(3):228-37. doi: 10.1016/j.scijus.2014.02.009. 

Spadoni G, Bedini A, Bartolucci S, Pala D, Mor M, Riccioni T, Borsini F, Cabri W, Celona D, Marzi M, Tarzia G, Rivara S, Minetti P Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties. Eur J Med Chem. 2014 Jun 10;80:8-35. doi: 10.1016/j.ejmech.2014.04.034

Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol. 2014 Dec;171(23):5195-208. doi: 10.1111/bph.12669. 

Ponzano S, Bertozzi F, Mengatto L, Dionisi M, Armirotti A, Romeo E, Berteotti  A, Fiorelli C, Tarozzo G, Reggiani A, Duranti A, Tarzia G, Mor M, Cavalli A, Piomelli D, Bandiera T. Synthesis and Structure-Activity Relationship (SAR) of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters, a Class of Potent N-Acylethanolamine Acid Amidase (NAAA) Inhibitors. J Med Chem. 2013 

Vacondio F, Carmi C, Galvani E, Bassi M, Silva C, Lodola A, Rivara S, Cavazzoni A, Alfieri RR, Petronini PG, Mor M. Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Bioorg Med Chem Lett. 2013 Aug 11. doi:pii: S0960-894X(13)00937-2. 10.1016/j.bmcl.2013.08.008. 

Rossi A, Buttini F, Colombo P, Mor M, Pala D, Bortolotti F, Colombo G. Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. Int J Pharm. 2013 Jul 15;451(1-2):50-6. doi: 10.1016/j.ijpharm.2013.04.064. 

Moreno-Sanz G, Duranti A, Melzig L, Fiorelli C, Ruda GF, Colombano G, Mestichelli P, Sanchini S, Tontini A, Mor M, Bandiera T, Scarpelli R, Tarzia G, Piomelli D. Synthesis and Structure-Activity Relationship Studies of O-Biphenyl-3-yl Carbamates as Peripherally Restricted Fatty Acid Amide Hydrolase  Inhibitors. J Med Chem. 2013 Jul 3. 

Chudyk EI, Dyguda-Kazimierowicz E, Langner KM, Sokalski WA, Lodola A, Mor M, Sirirak J, Mulholland AJ. Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase. J Phys Chem B. 2013 Jun 6;117(22):6656-66. doi: 10.1021/jp401834v. 

Pizzirani D, Pagliuca C, Realini N, Branduardi D, Bottegoni G, Mor M, Bertozzi F, Scarpelli R, Piomelli D, Bandiera T. Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR). J Med Chem. 2013 May 9;56(9):3518-30. doi: 10.1021/jm301879g. 

Pala D, Beuming T, Sherman W, Lodola A, Rivara S, Mor M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J Chem Inf Model. 2013 Apr 22;53(4):821-35. doi: 10.1021/ci4000147. 

Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S, Rivara S, Barocelli E, Mor M, Lodola A. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. doi: 10.1021/jm301890k. 

Lodola A, Capoferri L, Rivara S, Tarzia G, Piomelli D, Mulholland A, Mor M. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. J Med Chem. 2013 Mar 28;56(6):2500-12. doi: 10.1021/jm301867x. 

Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain. 2013 Mar;154(3):350-60. doi: 10.1016/j.pain.2012.10.018. PubMed PMID: 23218523; PubMed Central PMCID: PMC3723234.

Rivara S, Piersanti G, Bartoccini F, Diamantini G, Pala D, Riccioni T, Stasi  MA, Cabri W, Borsini F, Mor M, Tarzia G, Minetti P. Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. J Med Chem. 2013 Feb 14;56(3):1247-61. doi: 10.1021/jm301686s. PubMed PMID: 23281824. 

Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des. 2013;19(5):818-32. Review. PubMed PMID: 22973953.

Galvani E, Giovannetti E, Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri  R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Neoplasia. 2013 Jan;15(1):61-72. PubMed PMID: 23359111; PubMed Central PMCID: PMC3556939.   

Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, Fraschini  F, Mor M, Tarzia G, Gobbi G. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):318-25. doi: 10.1016/j.pnpbp.2012.07.003. PubMed PMID: 22789661.

Carmi C, Mor M, Petronini PG, Alfieri RR. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol. 2012 Dec 1;84(11):1388-99. doi: 10.1016/j.bcp.2012.07.031. Review. PubMed PMID: 22885287. 

Bartoccini F, Piersanti G, Mor M, Tarzia G, Minetti P, Cabri W. Divergent synthesis of novel 9-deazaxanthine derivatives via late-stage cross-coupling reactions. Org Biomol Chem. 2012 Nov 28;10(44):8860-7. doi: 10.1039/c2ob26516h. PubMed PMID: 23047760.

Rivara S, Pala D, Lodola A, Mor M, Lucini V, Dugnani S, Scaglione F, Bedini A, Lucarini S, Tarzia G, Spadoni G. MT(1) Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-{[(3-O-Substituted)anilino]alkyl}amides. ChemMedChem. 2012 Aug 27. doi: 10.1002/cmdc.201200303. [Epub ahead of print] PubMed PMID: 22927210. 

Vacondio F, Silva C, Flammini L, Ballabeni V, Barocelli E, Mor M. Brain pharmacokinetics of non-imidazole biphenyl H3 receptor antagonists: a liquid chromatography/electrospray-mass spectrometry and ex vivo binding study in rats.  Chem Biodivers. 2012 Jul;9(7):1231-9. doi: 10.1002/cbdv.201100242. PubMed PMID: 22782872. 

Tognolini M, Incerti M, Hassan-Mohamed I, Giorgio C, Russo S, Bruni R, Lelli  B, Bracci L, Noberini R, Pasquale EB, Barocelli E, Vicini P, Mor M, Lodola A. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem. 2012 Jun;7(6):1071-83. doi: 10.1002/cmdc.201200102. PubMed PMID: 22529030; PubMed Central PMCID: PMC3677030. 

Duranti A, Tontini A, Antonietti F, Vacondio F, Fioni A, Silva C, Lodola A, Rivara S, Solorzano C, Piomelli D, Tarzia G, Mor M. N-(2-oxo-3-oxetanyl)carbamic  acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. J Med Chem. 2012 May 24;55(10):4824-36. doi: 10.1021/jm300349j. PubMed PMID: 22515328. 

Carmi C, Galvani E, Vacondio F, Rivara S, Lodola A, Russo S, Aiello S, Bordi  F, Costantino G, Cavazzoni A, Alfieri RR, Ardizzoni A, Petronini PG, Mor M. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. J Med Chem. 2012 Mar 8;55(5):2251-64. doi: 10.1021/jm201507x. PubMed PMID: 22280453. 

Bordi F, Rivara S, Dallaturca E, Carmi C, Pala D, Lodola A, Vacondio F, Flammini L, Bertoni S, Ballabeni V, Barocelli E, Mor M. Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. Eur J Med Chem. 2012 Feb;48:214-30. doi: 10.1016/j.ejmech.2011.12.019. PubMed PMID: 22222138. 

Lodola A, Branduardi D, De Vivo M, Capoferri L, Mor M, Piomelli D, Cavalli A. A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. PLoS One. 2012;7(2):e32397. doi: 10.1371/journal.pone.0032397. PubMed PMID: 22389698; PubMed Central PMCID: PMC3289653. 

Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, Lodola A, Armirotti A, Garau G, Bandiera T, Reggiani A, Mor M, Cavalli A, Piomelli D. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci. 2012;15(1):64-9. doi: 10.1038/nn.2986. PubMed PMID: 22101642; PubMed Central PMCID: PMC3245783. 

Bedini A, Lucarini S, Spadoni G, Tarzia G, Scaglione F, Dugnani S, Pannacci M, Lucini V, Carmi C, Pala D, Rivara S, Mor M. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. J Med Chem. 2011 Dec 22;54(24):8362-72. doi: 10.1021/jm200790v. PubMed PMID: 22047556. 

Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, Rivara S, Bedini A, Angeloni D, Fraschini F, Mor M, Tarzia G, Descarries L, Gobbi G. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011 Dec 14;31(50):18439-52. doi: 10.1523/JNEUROSCI.2676-11.2011. PubMed PMID: 22171046. 

Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011 Dec;17(6):733-41. doi: 10.1111/j.1755-5949.2010.00197.x. Review. PubMed PMID: 21554566. 

Alfieri RR, Galetti M, Tramonti S, Andreoli R, Mozzoni P, Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Galvani E, De Palma G, Mutti A, Mor M, Tiseo M, Mari E, Ardizzoni A, Petronini PG. Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer. 2011 Nov 23;10:143. doi: 10.1186/1476-4598-10-143. PubMed PMID: 22111840; PubMed Central PMCID: PMC3281800. 

Palermo G, Branduardi D, Masetti M, Lodola A, Mor M, Piomelli D, Cavalli A, De Vivo M. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. J Med Chem. 2011 Oct 13;54(19):6612-23. doi: 10.1021/jm2004283. PubMed PMID: 21830831. 

Curti C, Battistini L, Sartori A, Lodola A, Mor M, Rassu G, Pelosi G, Zanardi F, Casiraghi G. Catalytic, asymmetric hypervinylogous Mukaiyama aldol reactions of extended furan-based silyl enolates. Org Lett. 2011 Sep 2;13(17):4738-41. doi: 10.1021/ol2020626. PubMed PMID: 21834551. 

Vacondio F, Silva C, Lodola A, Carmi C, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Tarzia G, Mor M. Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. Eur J Med Chem. 2011 Sep;46(9):4466-73. doi: 10.1016/j.ejmech.2011.07.021. PubMed PMID: 21820769; PubMed Central PMCID: PMC3714604. 

Capoferri L, Mor M, Sirirak J, Chudyk E, Mulholland AJ, Lodola A. Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. J Mol Model. 2011 Sep;17(9):2375-83. doi: 10.1007/s00894-011-0981-z PubMed PMID: 21365225. 

Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G, Mor M, Rivara S, Lucini V, Pannacci M, Scaglione F. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. Bioorg Med Chem. 2011 Aug 15;19(16):4910-6. doi: 10.1016/j.bmc.2011.06.063. PubMed PMID: 21775151. 

Vacondio F, Silva C, Morini G, Bordi F, Flammini L, Barocelli E, Mor M. Liquid chromatography-mass spectrometric method for determination of the non-imidazole H3-receptor antagonist UPR1056 in rat plasma. J Sep Sci. 2011 Jul;34(14):1656-63. doi: 10.1002/jssc.201000845. PubMed PMID: 21648077. 

Lodola A, Capoferri L, Rivara S, Chudyk E, Sirirak J, Dyguda-Kazimierowicz E, Andrzej Sokalski W, Mileni M, Tarzia G, Piomelli D, Mor M, Mulholland AJ. Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. Chem Commun (Camb). 2011 Mar 7;47(9):2517-9. doi: 10.1039/c0cc04937a. PubMed PMID: 21240393.

Lodola A, Rivara S, Mor M. Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure. Adv Protein Chem Struct Biol. 2011;85:1-26. doi: 10.1016/B978-0-12-386485-7.00001-6. Review. PubMed PMID: 21920320. 

Vacondio F, Silva C, Mor M, Testa B. Qualitative structure-metabolism relationships in the hydrolysis of carbamates. Drug Metab Rev. 2010 Nov;42(4):551-89. doi: 10.3109/03602531003745960. Review. PubMed PMID: 20441444. 

Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M,  Tarzia G, Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010 Oct;13(10):1265-70. doi: 10.1038/nn.2632. PubMed PMID: 20852626; PubMed Central PMCID: PMC3260554. 

Solorzano C, Antonietti F, Duranti A, Tontini A, Rivara S, Lodola A, Vacondio F, Tarzia G, Piomelli D, Mor M. Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem. 2010 Aug 12;53(15):5770-81. doi: 10.1021/jm100582w. PubMed PMID: 20604568; PubMed Central PMCID: PMC2932887.

Mor M, Rivara S, Pala D, Bedini A, Spadoni G, Tarzia G. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. Expert Opin Ther Pat. 2010 Aug;20(8):1059-77. doi: 10.1517/13543776.2010.496455. Review. PubMed PMID: 20533893.

Galetti M, Alfieri RR, Cavazzoni A, La Monica S, Bonelli M, Fumarola C, Mozzoni P, De Palma G, Andreoli R, Mutti A, Mor M, Tiseo M, Ardizzoni A, Petronini PG. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.Biochem Pharmacol. 2010 Jul 15;80(2):179-87. doi: 10.1016/j.bcp.2010.03.033. PubMed PMID: 20363215. 

Carmi C, Cavazzoni A, Vezzosi S, Bordi F, Vacondio F, Silva C, Rivara S, Lodola A, Alfieri RR, La Monica S, Galetti M, Ardizzoni A, Petronini PG, Mor M. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem. 2010 Mar 11;53(5):2038-50. doi: 10.1021/jm901558p. PubMed PMID: 20151670. 

Lodola A, Sirirak J, Fey N, Rivara S, Mor, Mulholland AJ. Structural Fluctuations in Enzyme-Catalyzed Reactions: Determinants of Reactivity in Fatty Acid Amide Hydrolase from Multivariate Statistical Analysis of Quantum Mechanics/Molecular Mechanics Paths. J. Chem Theor Comput 2010, 6, 2948-2960.

Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo  R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20966-71. doi: 10.1073/pnas.0907417106. PubMed PMID: 19926854; PubMed Central PMCID: PMC2791595. 

King AR, Lodola A, Carmi C, Fu J, Mor M, Piomelli D. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol. 2009 Jul;157(6):974-83. doi: 10.1111/j.1476-5381.2009.00276.x.

King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, Qiu Y, Fu J, Mor M, Piomelli D. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol. 2009 Oct 30;16(10):1045-52. doi: 10.1016/j.chembiol.2009.09.012. PubMed PMID: 19875078; PubMed Central PMCID: PMC3034734.

Rivara S, Vacondio F, Fioni A, Silva C, Carmi C, Mor M, Lucini V, Pannacci M, Caronno A, Scaglione F, Gobbi G, Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem. 2009 Oct;4(10):1746-55. doi: 10.1002/cmdc.200900240. PubMed PMID: 19728346. 

Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, Sanchini S, Tarzia G, Mor M, Piomelli D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem. 2009 Sep;4(9):1505-13. doi: 10.1002/cmdc.200900210. PubMed PMID: 19637155; PubMed Central PMCID: PMC3016090.

Vacondio F, Silva C, Lodola A, Fioni A, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Mor M, Tarzia G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem. 2009 Sep;4(9):1495-504. doi: 10.1002/cmdc.200900120. PubMed PMID: 19554599; PubMed Central PMCID: PMC3517974.

Zuliani V, Carmi C, Rivara M, Fantini M, Lodola A, Vacondio F, Bordi F, Plazzi PV, Cavazzoni A, Galetti M, Alfieri RR, Petronini PG, Mor M. 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9. doi: 10.1016/j.ejmech.2009.01.035. PubMed PMID: 19268405.   

Rivara M, Zuliani V, Fantini M, Dallaturca E, Mor M. Chiral NMR discrimination of the diastereoisomeric salts of the H3-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. Magn Reson Chem. 2009 Jun;47(6):515-8. doi: 10.1002/mrc.2418. PubMed PMID: 19288549.

Lodola A, Mor M, Sirirak J, Mulholland AJ. Insights into the mechanism and inhibition of fatty acid amide hydrolase from quantum mechanics/molecular mechanics (QM/MM) modelling. Biochem Soc Trans. 2009 Apr;37(Pt 2):363-7. doi: 10.1042/BST0370363. Review. PubMed PMID: 19290863.

Valitutti G, Duranti A, Mor M, Piersanti G, Piomelli D, Rivara S, Tontini A, Tarzia G, Traldi P. The collisional behavior of ESI-generated protonated molecules of some carbamate FAAH inhibitors isosteres and its relationships with biological activity. J Mass Spectrom. 2009 Apr;44(4):561-5. doi: 10.1002/jms.1524. Erratum in: J Mass Spectrom. 2011 Aug;46(8):847. PubMed PMID: 19034887.

Lo Verme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu C,  Tarzia G, Piomelli D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009 Feb 1;19(3):639-43. doi: 10.1016/j.bmcl.2008.12.059. PubMed PMID: 19128970; PubMed Central PMCID: PMC3690177.

Mor M, Lodola A. Pharmacological tools in endocannabinoid neurobiology. Curr Top Behav Neurosci. 2009;1:87-110. doi: 10.1007/978-3-540-88955-7_4. PubMed PMID: 21104381.

Morini G, Comini M, Rivara M, Rivara S, Bordi F, Plazzi PV, Flammini L, Saccani F, Bertoni S, Ballabeni V, Barocelli E, Mor M. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. Bioorg Med Chem. 2008 Dec 1;16(23):9911-24. doi: 10.1016/j.bmc.2008.10.029. PubMed PMID:  18976927.

Mor M, Lodola A, Rivara S, Vacondio F, Duranti A, Tontini A, Sanchini S, Piersanti G, Clapper JR, King AR, Tarzia G, Piomelli D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem. 2008 Jun 26;51(12):3487-98. doi: 10.1021/jm701631z. Erratum in: J Med Chem. 2009 Jan 8;52(1):224. PubMed PMID: 18507372; PubMed Central PMCID: PMC3744893.

Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, Fumarola C, Frazzi R, Bonelli M, Bordi F, Lodola A, Mor M, Petronini PG. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther. 2008 Feb;7(2):361-70. doi: 10.1158/1535-7163.MCT-07-0477. PubMed PMID: 18281519.

Lodola A, Mor M, Rivara S, Christov C, Tarzia G, Piomelli D, Mulholland AJ. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb). 2008 Jan 14;(2):214-6. PubMed PMID: 18092091.   

Vacondio F, Silva C, Fioni A, Mor M, Rivara M, Bordi F, Flammini L, Ballabeni V, Barocelli E. Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. J Pharm Biomed Anal. 2008 Jan 7;46(1):200-5. PubMed PMID: 17959330.

Rivara M, Vacondio F, Silva C, Zuliani V, Fantini M, Bordi F, Plazzi PV, Bertoni S, Ballabeni V, Flammini L, Barocelli E, Mor M. Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor. Chem Biodivers. 2008 Jan;5(1):140-52. doi: 10.1002/cbdv.200890004. PubMed PMID: 18205116.

Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G. Melatonin receptor agonists:  SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68. Review. PubMed PMID: 18673165.

Rivara S, Lodola A, Mor M, Bedini A, Spadoni G, Lucini V, Pannacci M, Fraschini F, Scaglione F, Sanchez RO, Gobbi G, Tarzia G. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007 Dec 27;50(26):6618-26. PubMed PMID: 18052314.

King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, Astarita G, Geaga JA, Luecke H, Mor M, Tarzia G, Piomelli D. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol. 2007 Dec;14(12):1357-65. PubMed PMID: 18096504; PubMed Central PMCID: PMC2225625. 

Spadoni G, Bedini A, Diamantini G, Tarzia G, Rivara S, Lorenzi S, Lodola A, Mor M, Lucini V, Pannacci M, Caronno A, Fraschini F. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007 Dec;2(12):1741-9. PubMed PMID: 17907131. 

Valitutti G, Duranti A, Lodola A, Mor M, Piersanti G, Piomelli D, Rivara S, Tontini A, Tarzia G, Traldi P. Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate  FAAH inhibitors.J Mass Spectrom. 2007 Dec;42(12):1624-7. PubMed PMID: 18085570.

Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.Biol Psychiatry. 2007 Nov 15;62(10):1103-10. PubMed PMID: 17511970. 

Tarzia G, Antonietti F, Duranti A, Tontini A, Mor M, Rivara S, Traldi P, Astarita G, King A, Clapper JR, Piomelli D. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann Chim. 2007 Sep;97(9):887-94. PubMed PMID: 17970304.

Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther. 2007 Jul;322(1):236-42. PubMed PMID: 17412883.

Lodola A, Mor M, Zurek J, Tarzia G, Piomelli D, Harvey JN, Mulholland AJ. Conformational effects in enzyme catalysis: reaction via a high energy conformation in fatty acid amide hydrolase. Biophys J. 2007 Jan 15;92(2):L20-2. PubMed PMID: 17098788; PubMed Central PMCID: PMC1751413.

Bedini A, Spadoni G, Gatti G, Lucarini S, Tarzia G, Rivara S, Lorenzi S, Lodola A, Mor M, Lucini V, Pannacci M, Scaglione F. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. J Med Chem. 2006 Dec 14;49(25):7393-403. PubMed PMID: 17149869. 

Clapper JR, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol Res. 2006 Nov;54(5):341-4. PubMed PMID:  16935521. 

Carmi C, Cavazzoni A, Zuliani V, Lodola A, Bordi F, Plazzi PV, Alfieri RR, Petronini PG, Mor M. 5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorg Med Chem Lett. 2006 Aug 1;16(15):4021-5. PubMed PMID: 16713265. 

Morini G, Comini M, Rivara M, Rivara S, Lorenzi S, Bordi F, Mor M, Flammini L, Bertoni S, Ballabeni V, Barocelli E, Plazzi PV. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. Bioorg Med Chem Lett. 2006 Aug 1;16(15):4063-7. PubMed PMID: 16713264. 

Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, Rivara S, Tarzia G, Mor M, Piomelli D. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther. 2006 Aug;318(2):563-70. PubMed PMID: 16702440. 

Rivara S, Diamantini G, Di Giacomo B, Lamba D, Gatti G, Lucini V, Pannacci M, Mor M, Spadoni G, Tarzia G. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling  of a constrained chiral melatonin analogue. Bioorg Med Chem. 2006 May 15;14(10):3383-91. PubMed PMID: 16431121. 

Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006 Spring;12(1):21-38. Review. PubMed PMID: 16834756. 

Spadoni G, Diamantini G, Bedini A, Tarzia G, Vacondio F, Silva C, Rivara M, Mor M, Plazzi PV, Zusso M, Franceschini D, Giusti P. Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity. J Pineal Res. 2006 Apr;40(3):259-69. PubMed PMID: 16499563.

Rivara M, Zuliani V, Cocconcelli G, Morini G, Comini M, Rivara S, Mor M, Bordi F, Barocelli E, Ballabeni V, Bertoni S, Plazzi PV. Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. Bioorg Med Chem. 2006 Mar 1;14(5):1413-24. PubMed PMID: 16263297. 

Tarzia G, Duranti A, Gatti G, Piersanti G, Tontini A, Rivara S, Lodola A, Plazzi PV, Mor M, Kathuria S, Piomelli D. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem. 2006 Jan;1(1):130-9. PubMed PMID: 16892344.

Mor M, Rivara S, Lodola A, Lorenzi S, Bordi F, Plazzi PV, Spadoni G, Bedini A, Duranti A, Tontini A, Tarzia G. Application of 3D-QSAR in the rational design  of receptor ligands and enzyme inhibitors. Chem Biodivers. 2005 Nov;2(11):1438-51. PubMed PMID: 17191945.

Lorenzi S, Mor M, Bordi F, Rivara S, Rivara M, Morini G, Bertoni S, Ballabeni V, Barocelli E, Plazzi PV. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Bioorg Med Chem. 2005 Oct 1;13(19):5647-57. PubMed PMID: 16085419. 

Lodola A, Mor M, Hermann JC, Tarzia G, Piomelli D, Mulholland AJ. QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun (Camb). 2005 Sep 21;(35):4399-401. PubMed PMID: 16136230.

Makara JK, Mor M, Fegley D, Szabó SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF, Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci. 2005 Sep;8(9):1139-41. Erratum in: Nat Neurosci. 2007 Jan;10(1):134. PubMed PMID: 16116451.

Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005 Jun 23;435(7045):1108-12. PubMed PMID: 15973410. 

Rivara S, Lorenzi S, Mor M, Plazzi PV, Spadoni G, Bedini A, Tarzia G. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J Med Chem. 2005 Jun 16;48(12):4049-60. PubMed PMID: 15943478.

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic  acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005 Apr;313(1):352-8. PubMed PMID: 15579492. 

Basso E, Duranti A, Mor M, Piomelli D, Tontini A, Tarzia G, Traldi P. Tandem  mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom. 2004 Dec;39(12):1450-5. PubMed PMID: 15578755. 

Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, Piomelli D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling  studies. J Med Chem. 2004 Oct 7;47(21):4998-5008. PubMed PMID: 15456244.

Vacondio F, Mor M, Silva C, Zuliani V, Rivara M, Rivara S, Bordi F, Plazzi PV, Magnanini F, Bertoni S, Ballabeni V, Barocelli E, Carrupt PA, Testa B. Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. Eur J Pharm Sci. 2004 Sep;23(1):89-98. PubMed PMID: 15324926. 

Lucini V, Pannacci M, Scaglione F, Fraschini F, Rivara S, Mor M, Bordi F, Plazzi PV, Spadoni G, Bedini A, Piersanti G, Diamantini G, Tarzia G. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J Med Chem. 2004 Aug 12;47(17):4202-12. PubMed PMID: 15293992.

Amari G, Armani E, Ghirardi S, Delcanale M, Civelli M, Caruso PL, Galbiati E, Lipreri M, Rivara S, Lodola A, Mor M. Synthesis, pharmacological evaluation, and  structure-activity relationships of benzopyran derivatives with potent SERM activity. Bioorg Med Chem. 2004 Jul 15;12(14):3763-82. Erratum in: Bioorg Med Chem. 2004 Sep 15;12(18):5011. PubMed PMID: 15210143.

Mor M, Silva C, Vacondio F, Plazzi PV, Bertoni S, Spadoni G, Diamantini G, Bedini A, Tarzia G, Zusso M, Franceschini D, Giusti P. Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities. J Pineal Res. 2004 Mar;36(2):95-102. PubMed PMID: 14962060.

Mor M, Bordi F, Silva C, Rivara S, Zuliani V, Vacondio F, Rivara M, Barocelli E, Bertoni S, Ballabeni V, Magnanini F, Impicciatore M, Plazzi PV. Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. Bioorg Med Chem. 2004 Feb 15;12(4):663-74. PubMed PMID: 14759727.

Tarzia G, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Plazzi PV, Kathuria S, Piomelli D. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorg Med Chem. 2003 Sep 1;11(18):3965-73. PubMed PMID: 12927857.

Silva C, Mor M, Vacondio F, Zuliani V, Vincenzo Plazzi PV. pH-partition profiles of 4-(3-oxo-1,2-benzisothiazolin-2-yl)phenyl and phenoxyalkanoic acids. Farmaco. 2003 Sep;58(9):989-93. PubMed PMID: 13679196.

Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Plazzi PV, Park C, Kathuria S, Piomelli D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide  hydrolase inhibitors. J Med Chem. 2003 Jun 5;46(12):2352-60. PubMed PMID: 12773040.

Rivara S, Mor M, Silva C, Zuliani V, Vacondio F, Spadoni G, Bedini A, Tarzia G, Lucini V, Pannacci M, Fraschini F, Plazzi PV. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.J Med Chem. 2003 Apr 10;46(8):1429-39. PubMed PMID: 12672242.

Spadoni G, Bedini A, Piersanti G, Mor M, Rivara S, Tarzia G. Strategies leading to MT2 selective melatonin receptor antagonists. Adv Exp Med Biol. 2003;527:577-85. PubMed PMID: 15206776.

Mor M, Spadoni G, Diamantini G, Bedini A, Tarzia G, Silva C, Vacondio F, Rivara M, Plazzi PV, Franceschini D, Zusso M, Giusti P. Antioxidant and cytoprotective activity of indole derivatives related to melatonin. Adv Exp Med Biol. 2003;527:567-75. PubMed PMID: 15206775.

Rivara S, Mor M, Bordi F, Silva C, Zuliani V, Vacondio F, Morini G, Plazzi PV, Carrupt PA, Testa B. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a  neutral heterocyclic polar group. Drug Des Discov. 2003;18(2-3):65-79. PubMed PMID: 14675944.

Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat  Med. 2003 Jan;9(1):76-81. PubMed PMID: 12461523.